Results 201 to 210 of about 31,387 (227)

Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Yajima S, Hirose K, Masuda H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Current Therapy for Metastatic Urothelial Carcinoma

Hematology/Oncology Clinics of North America, 2021
Urothelial carcinoma (UC) is a highly lethal malignancy in the metastatic state. Platinum-based chemotherapy regimens have been the backbone treatment for patients with advanced UC in the first-line setting. However, a large subset of patients are suboptimal candidates for these combinations owing to poor renal function and/or other comorbidities ...
Rosa, Nadal, Joseph A, Clara, Begoña P, Valderrama, Joaquim, Bellmunt   +3 more
openaire   +2 more sources

Immunotherapy for advanced or metastatic urothelial carcinoma

Cochrane Database of Systematic Reviews, 2023
Immune checkpoint inhibitors are increasingly important in the treatment algorithm for locally advanced and metastatic bladder cancer. Numerous ongoing studies are investigating these agents as first- and second-line therapies, both alone and in combination with chemotherapy or in a maintenance therapy setting.To assess the effects of immune checkpoint
Philipp, Maisch, Eu Chang, Hwang, Kwangmin, Kim, Vikram M, Narayan, Caitlin, Bakker, Frank, Kunath, Philipp, Dahm   +6 more
openaire   +2 more sources

Metastatic Urothelial Carcinoma Presenting as Carcinoma Erysipeloides

Journal of Cutaneous Pathology, 2017
Carcinoma erysipeloides (CE) is a rare but distinctive form of cutaneous metastasis that clinically resembles erysipelas. Herein, we report a case of CE as the presenting feature of recurrent urothelial carcinoma.
Shane A. Grace, Matthew R. Livingood, Alan S. Boyd   +2 more
openaire   +2 more sources

First-line Immunotherapy in Metastatic Urothelial Carcinoma

European Urology Focus, 2020
Update on first-line immunotherapy in metastatic urothelial carcinoma.
Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth R. Plimack   +3 more
openaire   +2 more sources

Immunotherapy for Metastatic Urothelial Carcinoma

2021
Immunotherapy has revolutionized the management of urothelial carcinoma. In the last few years 5 immune checkpoint inhibitors have been developed and approved for the treatment of advanced urothelial cancer after demonstrating durable responses in a subset of patients.
Victor R. Adorno Febles, Arjun V. Balar
openaire   +1 more source

Systemic treatments for metastatic urothelial carcinoma

Expert Opinion on Pharmacotherapy, 2018
Urothelial carcinoma is one of the most common cancers in the western world and, until recently, had limited therapeutic options. The contemporary advancement of immune checkpoint inhibitors (ICI) has heralded a new era for these patients and represents a major shift in the evolving treatment landscape.This article provides a comprehensive summary of ...
Aly-Khan A. Lalani, Guru P. Sonpavde
openaire   +2 more sources

Atezolizumab for platinum-treated metastatic urothelial carcinoma

The Lancet, 2018
n ...
Massari F., Di Nunno V.
openaire   +2 more sources

Atezolizumab in invasive and metastatic urothelial carcinoma

Expert Review of Clinical Pharmacology, 2017
Until recently, there has been little advancement in the management of invasive and metastatic urothelial cancer in over 30 years, and outcomes with cisplatin-based chemotherapy remain unchanged. Inhibitors targeting PD-1 signaling on cytotoxic T-cells have revolutionized bladder cancer therapy leading to durable responses.
Michael, Crist, Arjun, Balar
openaire   +2 more sources